• Galectin Therapeutics set three AASLD Liver Meeting 2026 presentations for Nov. 5-9, focused on belapectin in MASH cirrhosis.
• Future presentations will highlight new analyses suggesting noninvasive risk models can help predict variceal development in compensated patients.
• Additional data will assess alignment between noninvasive models and invasive pressure measurements, supporting potential trial design and patient selection.
• A registrational Phase 3 protocol for belapectin to prevent disease progression in MASH cirrhosis with portal hypertension was submitted to the FDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9839109) on October 06, 2026, and is solely responsible for the information contained therein.